Search Results
CGP-52411 100mg 100mg | Purity Not Available
Adooq Bioscience
CGP-52411 10mg 10mg | Purity Not Available
Adooq Bioscience
Refametinib (RDEA-119, BAY 86-9766) 50mg 50mg | Purity Not Available
Adooq Bioscience
Refametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity.
More Information Supplier PageRefametinib (RDEA-119, BAY 86-9766) 25mg 25mg | Purity Not Available
Adooq Bioscience
Refametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity.
More Information Supplier PageRefametinib (RDEA-119, BAY 86-9766) 100mg 100mg | Purity Not Available
Adooq Bioscience
Refametinib, also known as RDEA119, BAY 86-9766, is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity.
More Information Supplier PageARRY-543 5mg 5mg | Purity Not Available
Adooq Bioscience
ARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including ErbB3, either directly or indirectly, and has potential advantages in treating tumors that signal through multiple ErbB family members.
More Information Supplier PageARRY-543 50mg 50mg | Purity Not Available
Adooq Bioscience
ARRY-543 is a novel, oral ErbB family inhibitor that, unlike approved ErbB inhibitors, targets all members of the ErbB family, including ErbB3, either directly or indirectly, and has potential advantages in treating tumors that signal through multiple ErbB family members.
More Information Supplier PageTafenoquine 10mg 10mg | Purity Not Available
Adooq Bioscience
Tafenoquine is an 8-aminoquinoline drug manufactured by GlaxoSmithKline that is being investigated as a potential treatment for malaria, as well as for malaria prevention.
More Information Supplier PageLetaxaban (TAK-442) 50mg 50mg | Purity Not Available
Adooq Bioscience
Letaxaban, also known as TAK-442, is a potent, selective, and orally active factor Xa inhibitor, which is a tetrahydropyrimidin-2(1H)-one derivative. TAK-442 inhibited endogenous FXa activity in platelet-poor human [half-maximal inhibitory concentration (IC(50)): 53 nM, TAK-442] and rat (IC(50): 32 nM, TAK-442) plasma.
More Information Supplier Page